Cyclin A as a Marker for Breast Cancer Prognosis
Author Information
Author(s): Paula Poikonen, J. Sjöström, R-M Amini, K. Villman, J. Ahlgren, C. Blomqvist
Primary Institution: Helsinki University Central Hospital
Hypothesis
We wanted to study cyclin A as a marker for prognosis and chemotherapy response.
Conclusion
Cyclin A is a good marker for tumor proliferation and prognosis in breast cancer, but it does not predict chemotherapy response.
Supporting Evidence
- A high cyclin A correlated significantly to a shorter time to first relapse.
- Cyclin A positivity was determined by immunohistochemistry.
- Cyclin A did not correlate to chemotherapy response or survival after treatment.
- High cyclin A score predicted a better chemotherapy response in other cancer types.
Takeaway
Cyclin A helps doctors understand how aggressive a breast cancer is, but it doesn't tell them how well chemotherapy will work.
Methodology
The study involved a randomized multicenter trial comparing docetaxel to sequential methotrexate-fluorouracil in advanced breast cancer, with cyclin A levels measured in tumor samples.
Limitations
Only 34% of patients had tumor samples available for analysis.
Participant Demographics
Women aged 18-70 with metastatic breast cancer.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI 1.24–3.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website